PHASE 1, DOSE-RANGING STUDY OF EMIXUSTAT HYDROCHLORIDE (ACU-4429), A NOVEL VISUAL CYCLE MODULATOR, IN HEALTHY VOLUNTEERS
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
In Brief Background: Emixustat hydrochloride (formerly ACU-4429) is a nonretinoid compound with a unique mode of action in the retinal pigment epithelium, where it modulates the biosynthesis of visual chromophore through its effect on retinal pigment epithelium-specific 65 kDa protein isomerase. This study provides clinicians with a background for understanding the pharmacokinetics and safety profile of orally administered emixustat. Methods: This randomized, double-masked, placebo-controlled Phase 1b study evaluated the pharmacokinetics, tolerability, and safety of a 14-day course of oral emixustat (5, 10, 20, 30, or 40 mg) or placebo (3:1 ratio) once daily in healthy volunteers. Results: A total of 40 subjects were enrolled (mean age, 38 years; 75% male). Emixustat (n = 30) was rapidly absorbed (median Tmax, 3.0–5 hours) and readily eliminated (mean t1/2, 4.6–7.9 hours), and mean Cmax and AUC0–24 generally increased in proportion to dose. No significant accumulation of emixustat was observed with multiple-dose administration. Ocular adverse events occurred in 67% of the subjects who received emixustat; all were considered mild and resolved after study completion. Systemic adverse events were minimal. Conclusion: Oral emixustat was safe and well tolerated when administered once daily for 14 days with minimal systemic adverse events reported. These data support evaluation of emixustat in subjects with geographic atrophy associated with dry age-related macular degeneration. Emixustat hydrochloride (formerly ACU-4429) is a novel oral drug being studied as a therapy for the treatment of geographic atrophy associated with dry age-related macular degeneration. In this Phase 1b study, oral emixustat (5–40 mg) administered once daily for 14 days was safe and well tolerated in healthy volunteers. Emixustat was rapidly absorbed and readily eliminated, and did not accumulate with repeated-dose administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current concepts in the pathogenesis of age-related macular degeneration
Zarbin, M. A. (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.598 · Cited by 1,006
Holz, F. G., Bindewald-Wittich, A., Fleckenstein, M., Dreyhaupt, J., Scholl, H. P. N., & Schmitz-Valckenberg, S. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.11.041 · Cited by 619
A2E, a byproduct of the visual cycle
Sparrow, J. R., Fishkin, N., Zhou, J., Cai, B., Jang, Y. P., Krane, S., Itagaki, Y., & Nakanishi, K. (2003) · Vision Research · doi:10.1016/s0042-6989(03)00475-9 · Cited by 318 · cited 1×
“Bis-retinoids such as A2E, are formed through normal activity of the visual cycle.(16) Therefore, slowing visual cycle activity is expected to reduce accumulation of these compounds.”
BackgroundRadu, R. A., Mata, N. L., Nusinowitz, S., Liu, X., Sieving, P. A., & Travis, G. H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737855100 · Cited by 227
Tsybovsky, Y., Molday, R. S., & Palczewski, K. (2010) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4419-5635-4_8 · Cited by 200
Mata, N. L., Lichter, J. B., Vogel, R., Han, Y., Bui, T. V., & Singerman, L. J. (2013) · Retina · doi:10.1097/iae.0b013e318265801d · Cited by 157 · cited 1×
“This mechanism of emixustat action is distinct from that of fenretinide, which acts systemically to reduce delivery of vitamin A to the eye.(21,22) Based on fenretinide’s mode of action, and the fact that fenretinide does not interact with any enzymes or proteins of the visual cycle,(21) it is not considered a true vi…”
BackgroundGolczak, M., Maeda, A., Bereta, G., Maeda, T., Kiser, P. D., Hunzelmann, S., von Lintig, J., Blaner, W. S., & Palczewski, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708982200 · Cited by 93
Cited by
Cremers, F. P. M., Lee, W., Collin, R. W. J., & Allikmets, R. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100861 · Cited by 315
Molecular pharmacodynamics of emixustat in protection against retinal degeneration
Zhang, J., Kiser, P. D., Badiee, M., Palczewska, G., Dong, Z., Golczak, M., Tochtrop, G. P., & Palczewski, K. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80950 · Cited by 75
Therapy Approaches for Stargardt Disease
Piotter, E., McClements, M. E., & MacLaren, R. E. (2021) · Biomolecules · doi:10.3390/biom11081179 · Cited by 49
New GABA modulators protect photoreceptor cells from light-induced degeneration in mouse models
Schur, R. M., Gao, S., Yu, G., Chen, Y., Maeda, A., Palczewski, K., & Lu, Z.-R. (2018) · The FASEB Journal · doi:10.1096/fj.201701250r · Cited by 19
Metadata
- Authors
- Kubota, R., Al-Fayoumi, S., Mallikaarjun, S., Patil, S., Bavik, C., & Chandler, J. W.
- Venue
- Retina
- Published
- 2014-03
- Volume
- 34
- Issue
- 3
- Pages
- 603-609
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W1981544118
- Cited by
- 73
- References
- 7
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PHASE 1, DOSE-RANGING STUDY OF EMIXUSTAT HYDROCHLORIDE (ACU-4429), A NOVEL VISUAL CYCLE MODULATOR, IN HEALTHY VOLUNTEERS. https://app.cochat.ai/papers/10.1097/01.iae.0000434565.80060.f8
- The paper
- Kubota, R., Al-Fayoumi, S., Mallikaarjun, S., Patil, S., Bavik, C., & Chandler, J. W. (2014). PHASE 1, DOSE-RANGING STUDY OF EMIXUSTAT HYDROCHLORIDE (ACU-4429), A NOVEL VISUAL CYCLE MODULATOR, IN HEALTHY VOLUNTEERS. Retina. https://doi.org/10.1097/01.iae.0000434565.80060.f8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.